Subscribe
shutterstock_1425438833_ii-studio
II.studio / Shutterstock.com
28 April 2020AmericasRory O'Neill

Argentum can't bring Gilenya patent challenge

Argentum Pharmaceuticals can’t have a  Novartis patent for a multiple sclerosis drug invalidated because it doesn’t have standing to bring the challenge, the US Court of Appeals for the Federal Circuit has ruled.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Pfizer fails to establish standing for patent challenge
28 April 2020   Pfizer has been rebuked by judges for filing thin evidence in support of what the pharma company called its ‘self-evident’ standing to bring a patent challenge.
Americas
Novartis tries to block generic versions of Gilenya, enforces new patent
30 January 2020   Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Pfizer fails to establish standing for patent challenge
28 April 2020   Pfizer has been rebuked by judges for filing thin evidence in support of what the pharma company called its ‘self-evident’ standing to bring a patent challenge.
Americas
Novartis tries to block generic versions of Gilenya, enforces new patent
30 January 2020   Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.

More on this story

Americas
Pfizer fails to establish standing for patent challenge
28 April 2020   Pfizer has been rebuked by judges for filing thin evidence in support of what the pharma company called its ‘self-evident’ standing to bring a patent challenge.
Americas
Novartis tries to block generic versions of Gilenya, enforces new patent
30 January 2020   Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent